Ogushi Tetsuo, Takahashi Satoru
Department of Urology, Toshiba General Hospital.
Hinyokika Kiyo. 2007 Dec;53(12):857-62.
Gosha-jinki-gan (GJG), a traditional Chinese medicine, is known to be potentially effective for urinary disturbance. For the clinical evaluation of Gosha-jinki-gan, we administered GJG for 6 weeks to elderly male patients with overactive bladder (OAB) and assessed its efficacy and tolerability. In this study, 30 male patients with over 6 months of OAB symptoms had received 2.5 g GJG mixture x 3/day. After 6 weeks of treatment, the efficacy, safety, and tolerability were assessed. We evaluated International Prostate Symptom Score (I-PSS), Overactive Bladder Symptom Score (OABSS), quality of life (QOL), maximal urinary flow rate (Qmax), average urinary flow rate (Qave), incidence of urinary incontinence, and post-void residual before and after treatment. We observed significant improvements in I-PSS (15.2 +/- 1.0 vs. 12.0 +/- 0.9, p < 0.0001), OABSS (7.5 +/- 0.6 vs. 4.9 +/- 0.5, p < 0.0001), and QOL score (4.4 +/- 1.0 vs. 3.3 +/- 1.1, p < 0.0001, Wilcoxon rank sum test). GJG was significantly effective in improving urgency, micturition frequency, nocturia, and urinary incontinence (p < 0.05). However, Qmax, Qave, and post void residual did not significantly change. Mild adverse effects were observed in 3 cases. The symptoms were diarrhea, nausea, and urinary frequency. These data suggest that Gosha-jinki-gan may be a new potential therapeutic agent for OAB without deterioration of voiding function in men with benign prostatic obstruction (BPO).
汉方制剂还少丹(GJG)是一种传统中药,已知对排尿障碍可能有效。为了对还少丹进行临床评估,我们对老年男性膀胱过度活动症(OAB)患者给予GJG治疗6周,并评估其疗效和耐受性。在本研究中,30例有超过6个月OAB症状的男性患者接受了2.5 g GJG合剂,每日3次。治疗6周后,评估疗效、安全性和耐受性。我们评估了治疗前后的国际前列腺症状评分(I-PSS)、膀胱过度活动症症状评分(OABSS)、生活质量(QOL)、最大尿流率(Qmax)、平均尿流率(Qave)、尿失禁发生率和残余尿量。我们观察到I-PSS(15.2±1.0对12.0±0.9,p<0.0001)、OABSS(7.5±0.6对4.9±0.5,p<0.0001)和QOL评分(4.4±1.0对3.3±1.1,p<0.0001,Wilcoxon秩和检验)有显著改善。GJG在改善尿急、排尿频率、夜尿症和尿失禁方面有显著效果(p<0.05)。然而,Qmax、Qave和残余尿量没有显著变化。3例出现轻度不良反应。症状为腹泻、恶心和尿频。这些数据表明,还少丹可能是一种治疗OAB的新的潜在治疗药物,对良性前列腺梗阻(BPO)男性的排尿功能无恶化作用。